Enanta Pharmaceuticals Inc expected to post a loss of $1.16 a share - Earnings Preview

Enanta Pharmaceuticals

22/11/2024 21:12

* Enanta Pharmaceuticals Inc  ENTA.OQ   ENTA.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 25 for the period ending September 30 2024
    * The Watertown Massachusetts-based  company is expected to
report
a 5.3% decrease in revenue to $17.932 million from $18.93
million a year ago, according to the mean estimate from 7
analysts, based on LSEG data.
    * ​LSEG's mean analyst estimate for Enanta Pharmaceuticals
Inc is
for a loss of $1.16 per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 3
"hold" and 1 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Enanta
Pharmaceuticals Inc is $22.00​, above​ its last closing price
of $9.31. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Jun. 30 2024  -1.40       -1.45      -1.07     Beat    26.2
 Mar. 31 2024  -1.39       -1.30      -1.47     Missed  -13.2
 Dec. 31 2023  -1.19       -1.19      -1.58     Missed  -32.3​
 Sep. 30 2023  -2.17       -2.15      -1.33     Beat    38
 ​​Jun.        -2.37       -2.34      -1.86     Beat    20.4
 30 2023                                                
 Mar. 31 2023  -1.94       -1.98      -1.79     Beat    9.6​
 Dec. 31 2022  -1.59       -1.59      -1.39     Beat    12.9
 Sep. 30 2022  -1.40       -1.35      -1.27     Beat    6.1
 This summary was machine generated November 22 at 21:12 GMT. 
All figures in US dollars unless otherwise stated. (For
questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)